CSIMarket
 


Vertex Pharmaceuticals Inc  (VRTX)
Other Ticker:  
 
 

VRTX's Revenue Growth by Quarter and Year

Vertex Pharmaceuticals Inc's Revenue results by quarter and year




VRTX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 2,517.70 2,302.70 2,072.56 1,627.82
III Quarter September 2,483.50 2,334.30 1,984.16 1,538.27
II Quarter June 2,493.20 2,196.20 1,793.37 1,524.49
I Quarter March 2,374.80 2,097.50 1,724.31 1,515.11
FY   9,869.20 8,930.70 7,574.40 6,205.69



VRTX Revenue fourth quarter 2023 Y/Y Growth Comment
Vertex Pharmaceuticals Inc reported Revenue growth of 9.34% year on year in the fourth quarter 2023, to $ 2,517.70 millions, this is lower than Vertex Pharmaceuticals Inc's recent average Revenue improvement of 31.61%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue growth. While Vertex Pharmaceuticals Inc' s Revenue increase of 9.34% ranks overall at the positon no. 399 in the fourth quarter 2023.




VRTX Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 9.34 % 11.1 % 27.32 % 15.18 %
III Quarter September 6.39 % 17.65 % 28.99 % 61.95 %
II Quarter June 13.52 % 22.46 % 17.64 % 61.96 %
I Quarter March 13.22 % 21.64 % 13.81 % 76.5 %
FY   10.51 % 17.91 % 22.06 % 49.07 %

Financial Statements
Vertex Pharmaceuticals Inc's fourth quarter 2023 Revenue $ 2,517.70 millions VRTX's Income Statement
Vertex Pharmaceuticals Inc's fourth quarter 2022 Revenue $ 2,302.70 millions Quarterly VRTX's Income Statement
New: More VRTX's historic Revenue Growth >>


VRTX Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 1.38 % -1.35 % 4.46 % 5.82 %
III Quarter September -0.39 % 6.29 % 10.64 % 0.9 %
II Quarter June 4.99 % 4.71 % 4.01 % 0.62 %
I Quarter March 3.13 % 1.2 % 5.93 % 7.21 %
FY (Year on Year)   10.51 % 17.91 % 22.06 % 49.07 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #38
Overall #399

Revenue Y/Y Growth Statistics
High Average Low
147.95 % 31.61 % -67.04 %
(June 30. 2016)   (Sep. 30, 2014)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #38
Overall #399
Revenue Y/Y Growth Statistics
High Average Low
147.95 % 31.61 % -67.04 %
(June 30. 2016)   (Sep. 30, 2014)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Vertex Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
86.55 % 5.76 % -78.5 %
(Sep 30 2015)  


VRTX's IV. Quarter Q/Q Revenue Comment
Vertex Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue growth of 1.38% quarter on quarter, to $ 2,517.70 millions.

Even if the IV. Quarter 2023 results were beneath the regular , this was still promising news, as the IV. Quarter expension, transcends the -1.35% growth in the IV. Quarter a year ago

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 341.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #39
Overall #341
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #39
Overall #341
Revenue Q/Q Growth Statistics
High Average Low
86.55 % 5.76 % -78.5 %
(Sep 30 2015)  


VRTX's IV. Quarter Q/Q Revenue Comment
Vertex Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue growth of 1.38% quarter on quarter, to $ 2,517.70 millions.

IV. Quarter 2023 Vertex Pharmaceuticals Inc's results seem to be contradictory, albeit below the ordinary, yet it shows a quite improvement relative to the -1.35% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 341.


Vertex Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 9,869.20 $ 9,654.20 $ 9,505.00 $ 9,208.00 $ 8,930.70
Y / Y Revenue Growth (TTM) 10.51 % 10.96 % 13.83 % 15.86 % 17.91 %
Year on Year Revenue Growth Overall Ranking # 116 # 345 # 173 # 322 # 681
Seqeuential Revenue Change (TTM) 2.23 % 1.57 % 3.23 % 3.11 % 2.65 %
Seq. Revenue Growth (TTM) Overall Ranking # 399 # 1448 # 564 # 2131 # 2136




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Vertex Pharmaceuticals Inc's cumulative twelve months Revenue were $ 9,869 millions, company would post below average annual Revenue growth of 2.65% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Vertex Pharmaceuticals Inc's Revenue growth from the 2483.5% growth in Sep 30 2023.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 116, from total ranking in previous quarter at 345.

Revenue TTM Q/Q Growth Statistics
High Average Low
147.95 %
31.61 %
-67.04 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 20
Overall # 116

Revenue TTM Y/Y Growth Statistics
High Average Low
147.95 %
31.61 %
-67.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 38
S&P 500 # 399
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Vertex Pharmaceuticals Inc's cumulative twelve months Revenue were $ 9,869 millions, company would post below average annual Revenue growth of -67.04% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Vertex Pharmaceuticals Inc's Revenue growth from the 2483.5% growth in Sep 30 2023.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 116, from total ranking in previous quarter at 345.

Revenue TTM Q/Q Growth Statistics
High Average Low
147.95 %
31.61 %
-67.04 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 20
Overall # 116

Revenue TTM Y/Y Growth Statistics
High Average Low
147.95 %
31.61 %
-67.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 38
S&P 500 # 399




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VRTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for VRTX's Competitors
Revenue Growth for Vertex Pharmaceuticals Inc's Suppliers
Revenue Growth for VRTX's Customers

You may also want to know
VRTX's Annual Growth Rates VRTX's Profitability Ratios VRTX's Asset Turnover Ratio VRTX's Dividend Growth
VRTX's Roe VRTX's Valuation Ratios VRTX's Financial Strength Ratios VRTX's Dividend Payout Ratio
VRTX's Roa VRTX's Inventory Turnover Ratio VRTX's Growth Rates VRTX's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Glaukos Corp15.55%$ 15.546 millions
Boston Scientific Corporation14.86%$ 14.863 millions
Steris Plc14.77%$ 14.774 millions
Teva Pharmaceutical Industries Limited14.76%$ 14.757 millions
C4 Therapeutics Inc 14.26%$ 14.261 millions
Edwards Lifesciences Corporation13.75%$ 13.751 millions
National Healthcare Corp13.74%$ 13.744 millions
Neuronetics inc 13.35%$ 13.348 millions
Exelixis Inc 13.15%$ 13.148 millions
Livanova Plc12.83%$ 12.832 millions
Innovage Holding Corp 12.80%$ 12.805 millions
Ati Physical Therapy Inc 12.69%$ 12.690 millions
Resmed Inc 12.42%$ 12.421 millions
Stryker Corp11.78%$ 11.784 millions
Msa Safety Incorporated11.66%$ 11.663 millions
Pro dex Inc 11.58%$ 11.576 millions
Integer Holdings Corporation10.87%$ 10.870 millions
Ufp Technologies Inc 10.79%$ 10.785 millions
Myriad Genetics Inc 10.57%$ 10.574 millions
Warby Parker Inc 10.51%$ 10.510 millions
Merit Medical Systems Inc10.44%$ 10.442 millions
Inotiv Inc 10.38%$ 10.384 millions
Haemonetics Corporation10.23%$ 10.226 millions
Kamada Ltd 10.19%$ 10.190 millions
Adapthealth Corp 9.99%$ 9.990 millions
Bausch Health Companies Inc 9.80%$ 9.804 millions
Ironwood Pharmaceuticals inc 9.66%$ 9.659 millions
Brookdale Senior Living Inc 9.58%$ 9.585 millions
Option Care Health Inc 9.52%$ 9.523 millions
Incyte Corporation9.35%$ 9.349 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com